FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3133668037> ?p ?o ?g. }

• W3133668037 endingPage "393" @default.
• W3133668037 startingPage "393" @default.
• W3133668037 abstract "Although fatigue is a common symptom in multiple sclerosis (MS), its pathomechanisms are incompletely understood. Glatiramer acetate (GA), an immunomodulatory agent approved for treatment of relapsing-remitting MS (RRMS), possesses unique mechanisms of action and has been shown to exhibit beneficial effects on MS fatigue. The objective of this study was to correlate clinical, neuropsychological, and immunological parameters in RRMS patients with fatigue before and during treatment with GA. In a prospective, open-label, multicenter trial, 30 patients with RRMS and fatigue were treated with GA for 12 months. Inclusion criterion was the presence of fatigue as one of the most frequent and disabling symptoms. Before and during treatment, fatigue was assessed using the Fatigue Severity Scale (FSS), the MS-FSS, and the Modified Fatigue Impact Scale (MFIS). In addition, fatigue and quality of life were assessed using the Visual Analog Scales (VAS). Laboratory assessments included screening of 188 parameters using real-time PCR microarrays followed by further analysis of several cytokines, chemokines, and neurotrophic factors. Fatigue self-assessments were completed in 25 patients. After 12 months of treatment with GA, 13 of these patients improved in all three scales (with the most prominent effects on the MFIS), whereas 5 patients had deteriorated. The remaining 7 patients exhibited inconsistent effects within the three scales. Fatigue and overall quality of life had improved, as assessed via VAS. Laboratory assessments revealed heterogeneous mRNA levels of cytokines, chemokines, and neurotrophic factors. In conclusion, we were not able to correlate clinical and molecular effects of GA in patients with RRMS and fatigue." @default.
• W3133668037 created "2021-03-15" @default.
• W3133668037 creator A5009657993 @default.
• W3133668037 creator A5021276100 @default.
• W3133668037 creator A5022145611 @default.
• W3133668037 creator A5030982118 @default.
• W3133668037 creator A5036633122 @default.
• W3133668037 creator A5055558719 @default.
• W3133668037 creator A5056088339 @default.
• W3133668037 creator A5063615479 @default.
• W3133668037 creator A5076348059 @default.
• W3133668037 creator A5085825554 @default.
• W3133668037 date "2021-03-07" @default.
• W3133668037 modified "2023-10-12" @default.
• W3133668037 title "Glatiramer Acetate Treatment in Multiple Sclerosis-Associated Fatigue—Beneficial Effects on Self-Assessment Scales But Not on Molecular Markers" @default.
• W3133668037 cites W129839485 @default.
• W3133668037 cites W1488617601 @default.
• W3133668037 cites W1970890878 @default.
• W3133668037 cites W1983334940 @default.
• W3133668037 cites W2005506388 @default.
• W3133668037 cites W2021435584 @default.
• W3133668037 cites W2027661319 @default.
• W3133668037 cites W2035409540 @default.
• W3133668037 cites W2037902784 @default.
• W3133668037 cites W2053117941 @default.
• W3133668037 cites W2067495470 @default.
• W3133668037 cites W2091012989 @default.
• W3133668037 cites W2108230902 @default.
• W3133668037 cites W2109155524 @default.
• W3133668037 cites W2112165124 @default.
• W3133668037 cites W2113842511 @default.
• W3133668037 cites W2114242035 @default.
• W3133668037 cites W2120265437 @default.
• W3133668037 cites W2134337525 @default.
• W3133668037 cites W2161060662 @default.
• W3133668037 cites W2165084047 @default.
• W3133668037 cites W2173662187 @default.
• W3133668037 cites W2507312414 @default.
• W3133668037 cites W2594896469 @default.
• W3133668037 cites W2739788940 @default.
• W3133668037 cites W2888355898 @default.
• W3133668037 cites W2892197227 @default.
• W3133668037 cites W2970106037 @default.
• W3133668037 cites W2996124872 @default.
• W3133668037 cites W3021074489 @default.
• W3133668037 cites W3023504150 @default.
• W3133668037 cites W3025052300 @default.
• W3133668037 cites W3026286169 @default.
• W3133668037 cites W3083663875 @default.
• W3133668037 cites W4253381763 @default.
• W3133668037 doi "https://doi.org/10.3390/biom11030393" @default.
• W3133668037 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8002075" @default.
• W3133668037 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33800033" @default.
• W3133668037 hasPublicationYear "2021" @default.
• W3133668037 type Work @default.
• W3133668037 sameAs 3133668037 @default.
• W3133668037 citedByCount "4" @default.
• W3133668037 countsByYear W31336680372021 @default.
• W3133668037 countsByYear W31336680372022 @default.
• W3133668037 countsByYear W31336680372023 @default.
• W3133668037 crossrefType "journal-article" @default.
• W3133668037 hasAuthorship W3133668037A5009657993 @default.
• W3133668037 hasAuthorship W3133668037A5021276100 @default.
• W3133668037 hasAuthorship W3133668037A5022145611 @default.
• W3133668037 hasAuthorship W3133668037A5030982118 @default.
• W3133668037 hasAuthorship W3133668037A5036633122 @default.
• W3133668037 hasAuthorship W3133668037A5055558719 @default.
• W3133668037 hasAuthorship W3133668037A5056088339 @default.
• W3133668037 hasAuthorship W3133668037A5063615479 @default.
• W3133668037 hasAuthorship W3133668037A5076348059 @default.
• W3133668037 hasAuthorship W3133668037A5085825554 @default.
• W3133668037 hasBestOaLocation W31336680371 @default.
• W3133668037 hasConcept C126322002 @default.
• W3133668037 hasConcept C14184104 @default.
• W3133668037 hasConcept C159110408 @default.
• W3133668037 hasConcept C185592680 @default.
• W3133668037 hasConcept C1862650 @default.
• W3133668037 hasConcept C203014093 @default.
• W3133668037 hasConcept C2778577042 @default.
• W3133668037 hasConcept C2779951463 @default.
• W3133668037 hasConcept C2780640218 @default.
• W3133668037 hasConcept C2781197716 @default.
• W3133668037 hasConcept C55493867 @default.
• W3133668037 hasConcept C71924100 @default.
• W3133668037 hasConceptScore W3133668037C126322002 @default.
• W3133668037 hasConceptScore W3133668037C14184104 @default.
• W3133668037 hasConceptScore W3133668037C159110408 @default.
• W3133668037 hasConceptScore W3133668037C185592680 @default.
• W3133668037 hasConceptScore W3133668037C1862650 @default.
• W3133668037 hasConceptScore W3133668037C203014093 @default.
• W3133668037 hasConceptScore W3133668037C2778577042 @default.
• W3133668037 hasConceptScore W3133668037C2779951463 @default.
• W3133668037 hasConceptScore W3133668037C2780640218 @default.
• W3133668037 hasConceptScore W3133668037C2781197716 @default.
• W3133668037 hasConceptScore W3133668037C55493867 @default.
• W3133668037 hasConceptScore W3133668037C71924100 @default.
• W3133668037 hasIssue "3" @default.
• W3133668037 hasLocation W31336680371 @default.

• next